MERCK & Co
Mr Nikos LioutasSenior Specialist - Digital Innovation & Outreach
Merck & Co.
Led >10 biologics PKPD mathematical modeling and data analysis projects in oncology, diabetes, inflammation and Alzheimer's disease.
- Conceived the idea for a novel technology in the area of antibody drug conjugates to specifically target the tumor cells. Gathered a team of 5 to implement the technology. Got buy-in from senior management. Based on this technology, an antibody drug is being developed in Pfizer (patent in preparation).
- Co-invented a technology to improve the dosing of antibody drugs (patent application filed). A drug based on this technology is in the pipeline.
Specialties: - Feasibility analysis: Assessment of new biotherapeutic drugs, modalities and technologies
- Mechanism based translation: Preclinical to phase 1 clinical trials
- Biotherapeutics PKPD
- Monoclonal antibody drug property and dose selection
- Use of predictive mathematical modeling to design bio-better therapeutics
- Business development: Due diligence for licensing opportunities
Kapil MayawalaPrincipal Scientist - Quantitative Modeling/Systems Pharmacology
Merck & Co., Inc.
Dr JoAnne FoodyGlobal Director for Scientific Affairs, Cardiovascular
Merck Animal Health
Our customers have always known that they can depend on Merck Animal Health for more than just medicines. They count on Merck Animal Health for information, technologies and veterinary services that truly advance animal healthcare. It is our heritage and our mission.
Today, our science supports the precious bond between people and their pets. It also helps protect international public health, ensure food safety and increase protein supplies.
Dr Holger LehmannAVP & Global Head, Drug Discovery
The insight you’ll gain from Mergermarket often doesn’t become public knowledge until 6-24 months after our journalists first report on it, giving you a large window of opportunity to take early action.
Our global team of dedicated M&A journalists uses its extensive network of industry contacts and executives to gather information about corporate strategy, providing a unique source of M&A intelligence.League tables
Because we’re always up to speed on which advisors are working which M&A deals, our detailed ‘Who’s who in M&A’ league tables have become an industry standard among investment professionals.
As a Mergermarket subscriber, you can custom-build individual or house league tables to analyze firm performance and enhance your marketing, competitor analysis or pitch book efforts.ECM
Our new ECM tab is more than just an origination tool. It’s an independent voice, delivering the ECM news and information you need, ahead of the market. Learn more about Mergermarket ECM.
Our multilingual team of journalists monitors more than 3,000 global media sources daily, summarizing the most relevant stories to supplement the information our correspondents provide.Deals database
Through Mergermarket, you can search a global library of historical M&A transactions with fully sourced financials and exit multiples. You can analyze volumes and values of M&A activity in specific regions or sectors to discover deal patterns and identify trends ahead of competitors.Private equity portfolio
Using Mergermarket’s customizable Private Equity Search facility, you can analyze over 1,000 of the world’s biggest private equity firms, looking at current portfolio, historical exits, potential investments, firm profile, historical advisor and investment relationships, and rival bidders.
What our subscribers say
"Being an international law firm, we value Mergermarket as an important resource for real time deal intelligence across borders."
Mr Dane HamiltonUS Healthcare editor
Midi Capital is a rapidly growing independent private equity company, specialized in financing small and medium businesses.
Midi Capital manages over € 260 million and a portfolio of investments of 120 small and medium companies covering a wide range of industrial and service sectors (Medical & Life Science, Digital & media, Brands & Retail) .
In 6 métropoles (Barcelone, Lyon, Paris, Toulouse, Marseille, Nice) our teams (40 people) work with a wide range of entrepreneurs and company cultures. But we all share a common ambition: help our entrepreneurs to be and remain the leaders they want to be, to lead the change.
small and medium businesses.
Jean Baptiste FREYInvestment Manager
Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.
Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.